Javascript must be enabled to continue!
Temporal determinants of tumour response to neoadjuvant rectal radiotherapy
View through CrossRef
Introduction
In locally advanced rectal cancer, longer delay to surgery after neoadjuvant radiotherapy increases the likelihood of histopathological tumour response. Chronomodulated radiotherapy in rectal cancer has recently been reported as a factor increasing tumour response to neoadjuvant treatment in patients having earlier surgery, with patients receiving a larger proportion of afternoon treatments showing improved response. This paper aims to replicate this work by exploring the impact of these two temporal factors, independently and in combination, on histopathological tumour response in rectal cancer patients.
Methods
A retrospective review of all patients with rectal adenocarcinoma who received long course (≥24 fractions) neoadjuvant radiotherapy with or without chemotherapy at a tertiary referral centre was conducted. Delay to surgery and radiotherapy treatment time were correlated to clinicopathologic characteristics with a particular focus on tumour regression grade. A review of the literature and meta-analysis were also conducted to ascertain the impact of time to surgery from preoperative radiotherapy on tumour regression.
Results
From a cohort of 367 patients, 197 patients met the inclusion criteria. Complete pathologic response (AJCC regression grade 0) was seen in 46 (23%) patients with a further 44 patients (22%) having at most small groups of residual cells (AJCC regression grade 1). Median time to surgery was 63 days, and no statistically significant difference was seen in tumour regression between patients having early or late surgery. There was a non-significant trend towards a larger proportion of morning treatments in patients with grade 0 or 1 regression (p = 0.077). There was no difference in tumour regression when composite groups of the two temporal variables were analysed. Visualisation of data from 39 reviewed papers (describing 27379 patients) demonstrated a plateau of response to neoadjuvant radiotherapy after approximately 60 days, and a meta-analysis found improved complete pathologic response in patients having later surgery.
Conclusions
There was no observed benefit of chronomodulated radiotherapy in our cohort of rectal cancer patients. Review of the literature and meta-analysis confirms the benefit of delayed surgery, with a plateau in complete response rates at approximately 60-days between completion of radiotherapy and surgery. In our cohort, time to surgery for the majority of our patients lay along this plateau and this may be a more dominant factor in determining response to neoadjuvant therapy, obscuring any effects of chronomodulation on tumour response. We would recommend surgery be performed between 8 and 11 weeks after completion of neoadjuvant radiotherapy in patients with locally advanced rectal cancer.
Public Library of Science (PLoS)
Title: Temporal determinants of tumour response to neoadjuvant rectal radiotherapy
Description:
Introduction
In locally advanced rectal cancer, longer delay to surgery after neoadjuvant radiotherapy increases the likelihood of histopathological tumour response.
Chronomodulated radiotherapy in rectal cancer has recently been reported as a factor increasing tumour response to neoadjuvant treatment in patients having earlier surgery, with patients receiving a larger proportion of afternoon treatments showing improved response.
This paper aims to replicate this work by exploring the impact of these two temporal factors, independently and in combination, on histopathological tumour response in rectal cancer patients.
Methods
A retrospective review of all patients with rectal adenocarcinoma who received long course (≥24 fractions) neoadjuvant radiotherapy with or without chemotherapy at a tertiary referral centre was conducted.
Delay to surgery and radiotherapy treatment time were correlated to clinicopathologic characteristics with a particular focus on tumour regression grade.
A review of the literature and meta-analysis were also conducted to ascertain the impact of time to surgery from preoperative radiotherapy on tumour regression.
Results
From a cohort of 367 patients, 197 patients met the inclusion criteria.
Complete pathologic response (AJCC regression grade 0) was seen in 46 (23%) patients with a further 44 patients (22%) having at most small groups of residual cells (AJCC regression grade 1).
Median time to surgery was 63 days, and no statistically significant difference was seen in tumour regression between patients having early or late surgery.
There was a non-significant trend towards a larger proportion of morning treatments in patients with grade 0 or 1 regression (p = 0.
077).
There was no difference in tumour regression when composite groups of the two temporal variables were analysed.
Visualisation of data from 39 reviewed papers (describing 27379 patients) demonstrated a plateau of response to neoadjuvant radiotherapy after approximately 60 days, and a meta-analysis found improved complete pathologic response in patients having later surgery.
Conclusions
There was no observed benefit of chronomodulated radiotherapy in our cohort of rectal cancer patients.
Review of the literature and meta-analysis confirms the benefit of delayed surgery, with a plateau in complete response rates at approximately 60-days between completion of radiotherapy and surgery.
In our cohort, time to surgery for the majority of our patients lay along this plateau and this may be a more dominant factor in determining response to neoadjuvant therapy, obscuring any effects of chronomodulation on tumour response.
We would recommend surgery be performed between 8 and 11 weeks after completion of neoadjuvant radiotherapy in patients with locally advanced rectal cancer.
Related Results
Sequelae after multimodal treatment of rectal cancer
Sequelae after multimodal treatment of rectal cancer
<p dir="ltr">In recent decades, rectal cancer treatment has shifted from traditional surgical resection to include additional modalities such as radiotherapy and chemotherapy...
Sequelae after multimodal treatment of rectal cancer
Sequelae after multimodal treatment of rectal cancer
<p dir="ltr">In recent decades, rectal cancer treatment has shifted from traditional surgical resection to include additional modalities such as radiotherapy and chemotherapy...
Neoadjuvant Immunotherapy and Non–Small Cell Lung Cancer
Neoadjuvant Immunotherapy and Non–Small Cell Lung Cancer
Objectives:
To systematically evaluate the effectiveness and safety of neoadjuvant immunotherapy for patients with non–small cell lung cancer (NSCLC).
...
Impact on CD4+ CD25High-CD127low regulatory T (Treg) cells of neoadjuvant therapy for rectal cancer patients
Impact on CD4+ CD25High-CD127low regulatory T (Treg) cells of neoadjuvant therapy for rectal cancer patients
ABSTRACT
Background:
The efficacy of neoadjuvant therapy for rectal cancer has not been assessed.
Objective:
...
Core Biopsy Following Neoadjuvant Chemotherapy Predicts Tumour Response and Aids in Breast Preservation.
Core Biopsy Following Neoadjuvant Chemotherapy Predicts Tumour Response and Aids in Breast Preservation.
Abstract
Back groundAdvancement in chemotherapy regimens has improved pathological tumour response following neoadjuvant chemotherapy (NAC). This has subsequently he...
Abstract P4-06-06: Role of lymphatic SEC62 expression in prediction of treatment response in patients undergoing neoadjuvant chemotherapy for primary breast cancer
Abstract P4-06-06: Role of lymphatic SEC62 expression in prediction of treatment response in patients undergoing neoadjuvant chemotherapy for primary breast cancer
Abstract
Background Chromosome 3q26 amplifications have been shown to represent a frequent alteration in various cancer entities including breast cancer. SEC62 - a 3...
Quantitative Assessment of Rectal Dose–Volume Histogram (DVH) Constraint Deviations in Image-Guided Hypofractionated Prostate Radiotherapy
Quantitative Assessment of Rectal Dose–Volume Histogram (DVH) Constraint Deviations in Image-Guided Hypofractionated Prostate Radiotherapy
Introduction: We aimed to investigate changes in rectal dose during the treatment course for prostate cancer patients treated with hypofractionated radiotherapy with daily image-gu...
Complete Response Evaluation of Locally Advanced Rectal Cancer to
Neoadjuvant Chemoradiotherapy Using Textural Features Obtained from
T2 Weighted Imaging and ADC Maps
Complete Response Evaluation of Locally Advanced Rectal Cancer to
Neoadjuvant Chemoradiotherapy Using Textural Features Obtained from
T2 Weighted Imaging and ADC Maps
Background:
The prediction of pathological responses for locally advanced rectal cancer
using magnetic resonance imaging (MRI) after neoadjuvant chemoradiotherapy (CRT) is a challe...

